Local and Systemic Pharmacokinetic Profile of Dapivirine Vaginal Ring-004 When Used Continuously Over Various Periods up to Twelve Weeks
Background: Dapivirine Vaginal Ring-004 (25 mg dapivirine) is a topical microbicide being evaluated for safety and efficacy in a Phase III clinical program. The pharmacokinetic (PK) profile of Ring-004 has been described for up to 35 days of continuous use. This trial investigated the PK of dapivirine from Ring-004 for continuous use up to 12…